CAS: 26490-31-3; Nandrolone Laurate

该化合物是一种来自硝化酮的代谢类类固醇,这是一种天然的荷尔蒙睾酮的合成形式,其特点是用酸酸来酯化,这增加了其脂性,改变了其药用植物特性,导致体内释放速度放慢和延长行动时间. 硝化酮光化通常用于兽医医学,以促进肌肉生长和提高牲畜饲料效率. 其新陈性质性能使其对提高体育性能具有吸引力,尽管由于潜在的健康风险和伦理问题,在竞技体育中禁止使用它. 与睾丸酮相比,化合物的致癌活动较低,而且诱发性活动可能减少,并产生诱发性的副作用. 与其他新陈代谢类固醇一样,硝化酮光化可能对蛋白新陈代谢,肌肉超富营养性以及恢复产生重大影响,包括荷尔蒙不平衡和心血管问题. 在考虑任何情况下使用时,适当的调控和监测至关重要.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2025281509-A1
    优先权日:2021-04-26
    标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
    发明人:DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
    权利人:UNIV JOHNS HOPKINS
    摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    参考文献:10.1016/j.jsbmb.2007.09.024
    摘要:Pinel G, Rambaud L, Cacciatore G, Bergwerff A, Elliott C, Nielen M, Le Bizec B. Elimination kinetic of 17β-estradiol 3-benzoate and 17β-nandrolone laureate ester metabolites in calves’ urine. The Journal of Steroid Biochemistry and Molecular Biology. 2008 May;110(1-2):30–8. doi: 10.1016/j.jsbmb.2007.09.024.
    参考文献:10.1016/j.jsbmb.2010.01.012
    摘要:Pinel G, Rambaud L, Monteau F, Elliot C, Le Bizec B. Estranediols profiling in calves’ urine after 17β-nandrolone laureate ester administration. The Journal of Steroid Biochemistry and Molecular Biology. 2010 Aug;121(3-5):626–32. doi: 10.1016/j.jsbmb.2010.01.012.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知